Clinical trial
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
NCT00258960 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00258960 |
|---|---|
| Title | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer |
| Official title | Phase IV/II Trial With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab in Patients With Metastatic Breast Cancer With Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2)/Neu |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Liposomal Doxorubicin, Cyclophosphamide, Trastuzumab |
| Enrollment | 49 |
| Start date | Feb 15, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 14, 2009 |
| First posted | Nov 28, 2005 |
| Last update posted | Apr 4, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: